Results from drug repurposing screens using a yeast model of PGAP3 deficiency suggests cell death from ferroptosis as a pathomechanism, and phospholipase A2 activation as a therapeutic strategy.
We found PGAP3 yeast hits! Now what?
We found PGAP3 yeast hits! Now what?
We found PGAP3 yeast hits! Now what?
Results from drug repurposing screens using a yeast model of PGAP3 deficiency suggests cell death from ferroptosis as a pathomechanism, and phospholipase A2 activation as a therapeutic strategy.